High materiality7/10
Nurix Therapeutics price target raised to $31 from $23 at UBS
Why it may matterVerify against the original reporting
Upside expectation from target upgrade.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
UBS raises NRIX target to $31; current price $23.48; upside potential remains.
- Target: $31
- Posted price: $23.48
- Analyst: UBS
Key facts
- 01
Target: $31
- 02
Posted price: $23.48
- 03
Analyst firm: UBS
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.